The concept of HSD10 inhibition as a potential treatment for HSD10 overexpression associated with AD pathology was introduced several years ago [10, 24, 38, 44], and multiple classes of nanomolar inhibitors have since been developed [27, 30, 32]. Here, FSIP1 is linked to Alzheimer disease.